Table 2.

Clinicopathological characteristics disaggregated by TP53 status

	Total		Mutant signature		Wild-type signature		P*
	No. of patients	%	No. of patients	%	No. of patients	%
Samples	189	100	89	47	100	53
Age, years (median)	29–98 (58.0)		29–83 (59.0)		26–98 (56.0)		0.077
pStage							0.55
I	95	50	41	46	54	54
IIA	65	34	33	37	32	32
IIB	29	15	15	17	14	14
ER							< 0.0001
+	138	73	49	55	89	89
−	51	27	40	45	11	11
PgR							< 0.0001
+	101	54	34	38	67	67
−	88	46	55	62	33	33
HER2							0.025
+	18	10	13	15	5	5
−	171	90	76	85	95	95
Pathological tumor size, cm							0.78
≤ 2	125	66	59	66	66	66
> 2, ≤ 5	61	32	28	31	33	33
> 5	3	2	2	2	1	1
pLN							0.19
+	57	30	31	35	26	26
−	132	70	58	65	74	74
Grade							< 0.0001
1	46	25	8	9	38	40
2	82	45	29	33	53	55
3	55	30	50	57	5	5
NA	6		2		4
Histology							0.043
Invasive ductal carcinoma	179	95	85	96	94	94
Invasive lobular carcinoma	3	2	0	0	3	3
Medulary carcinoma	3	2	3	3	0	0
Mucinous	3	2	0	0	3	3
Undiff. carcinoma	1	1	1	1	0	0
Ki-67							< 0.0001
< 10	55	32	9	11	46	51
≥ 10	118	68	37	89	45	49
NA	16		7		9
Adjuvant chemotherapy							< 0.0001
+	86	46	54	61	32	32
−	103	54	35	39	68	68
Adjuvant endocrine therapy							< 0.0001
+	137	72	49	55	88	88
−	52	28	40	45	12	12

P* Chi-square test was used for statistical analysis of patients' characteristics except for age. Kruskal–Wallis test was used for statistical analysis of patients' age

pStage pathological stage, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor type 2, pLN pathological lymph node, NA not available